Timely Recovery After Subclinical Heart Failure

Launched by ACADEMISCH ZIEKENHUIS MAASTRICHT · Mar 25, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Timely Recovery After Subclinical Heart Failure," is looking at how effective a medication called ACE inhibitor (specifically Perindopril) is in helping women who have signs of heart failure but no symptoms (known as stage-B heart failure) or diastolic dysfunction. The study aims to see if taking this medication can improve heart function, prevent the development of symptoms, and enhance overall quality of life over two years. The trial will also explore various health factors and new biomarkers that can indicate heart issues.

Women aged 18 and older who have a history of preeclampsia or normal pregnancy and are between 0.5 to 30 years postpartum may be eligible to participate. Participants will be randomly assigned to either receive the medication or standard care without medication, and they will undergo regular health check-ups every six months during the study. This research is important because it could lead to better treatment options for women at risk of developing heart failure.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All women who visit Maastricht Univeristy Medical Center+ for Cardiovascular screening with subclinical/asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction;
• • Aged 18 years and older;
• • Premenopausal women with a history of preeclamptic pregnancy and premenopausal women with a history of normal pregnancy;
• • Between 0.5 and 30 years postpartum;
• Exclusion Criteria:
• • Intention to pursue pregnancy within 2 years;
• • Already using antihypertensive medication;
• • Suffering diabetes mellitus, kidney failure (GFR\<60 ml/min/1.73m2), pre-existent auto-immune disease and/or liver insufficiency;
• • Breastfeeding during participation;
• • Previous angio-edema